Announcement PDF Radiopharm Theranostics Limited ACN 647 877 889 2024 Environmental, Social and Governance Report 2 Environmental, Social, and Governance (ESG) Radiopharm Theranostics (“RAD”, “Radiopharm” or the “Company”) is committed to the principles of ESG as the most effective means of creating long-term enterprise value and addressing the societal priorities enshrined in the United Nations’ Sustainable Development Goals. In July 2021, we commenced reporting on selected Environmental, Social, and Governance (ESG) disclosures of the Stakeholder Capitalism Metrics (SCM) of the World Economic Forum (WEF). We continue to progress our disclosures in the form of a set of universal, comparable ESG metrics focused on people, planet, prosperity and principles of governance that organisations can report on regardless of industry or region. We use this universal ESG framework to align our mainstream reporting on performance against ESG indicators. We continue to look for opportunities for further transparency on the topics which are material to our business. Riccardo Canevari Chief Executive Officer and Managing Director 3 Governance Purpose Radiopharm is developing radiopharmaceutical products for both diagnostic and therapeutic uses in areas of high unmet medical needs. See also: • • www.radiopharmtheranostics.com/about-us www.radiopharmtheranostics.com/investors Governance Body Composition Radiopharm is governed by its Board of Directors and Committees of the Board. A description of director expertise, tenure, committee roles, meeting attendance, other significant positions and commitments and remuneration are outlined in the Annual Financial Report. The Board has referred to the guidance provided by the ASX Corporate Governance Council and acknowledges the recommendation that a majority of the Board of a listed entity should be independent and will work towards this outcome as the Company continues to grow. The skills and perspectives of our board members are important for ongoing decisions and governance, with respect to the everyday running of the company as well as important economic, environmental, and social topics. The Board is cognisant of maintaining a balance of diversity, skills, experience, and independence amongst its members. The process of formally integrating ESG competencies into the Board Skills Matrix is underway. See also: • • www.radiopharmtheranostics.com/our-team www.radiopharmtheranostics.com/investors Material Issues Impacting Stakeholders RAD is reviewing stakeholder mapping for disclosure in a future ESG report. Anti-Corruption Practices Radiopharm is committed to the highest standard of honesty and integrity. RAD’s commitment to the highest ethical standards includes strict compliance with applicable anti-bribery and corruption laws in Australia and overseas, acting in an ethical manner and acting with honesty, integrity, fairness, and respect. This commitment is reflected in the statement of values of the Company and in the formal Anti-Bribery and AntiCorruption Policy included in the Corporate Governance Framework. See also: • www.radiopharmtheranostics.com/investors 4 Mechanisms to Protect Ethical Behaviour Radiopharm is committed to the highest standards of honesty and ethical practices in all business activities. This is documented in the Company’s Corporate Governance Framework, which outlines Code of Conduct and Whistleblower Policy. Radiopharm’s Corporate Governance Framework can be found on the Radiopharm Theranostics website: • www.radiopharmtheranostics.com/investors Risk and Opportunity Oversight The Board is committed to the identification, assessment, and management of risk throughout the Company’s business activities. The Company’s Risk Management Policy recognises that risk management is an essential element of good corporate governance and fundamental in achieving its strategic and operational objectives. RAD’s Risk and Audit Committee reviews the risk management framework annually to satisfy itself that it continues to be sound. A summary of material risk is contained in the Annual Report. Radiopharm’s Corporate Governance Framework, outlining their Risk Management Policy can be found on the Radiopharm Theranostics website: • www.radiopharmtheranostics.com/investors 5 Planet GHG Emissions Radiopharm does not consider greenhouse gas (GHG) emissions to be a material stakeholder capitalism metric at this time, due to its small workforce and limited office-space footprint. RAD currently considers airline travel to be its highest GHG contribution and has therefore set a target for FY25 and beyond to always purchase carbon offsets for flights. TCFD Implementation RAD does not consider Task Force on Climate Related Financial Disclosures (TCFD) implementation to be a material stakeholder capitalism metric at this time, due to its small workforce, limited office-space footprint and limited exposure to risk and opportunities arising from climate change. Land Use and Key Biodiversity Areas Radiopharm does not consider land use and ecological sensitivity to be a material stakeholder capitalism metric at this time, as it operated from small offices in urban areas. Water Consumption Radiopharm does not consider water consumption to be a material stakeholder capitalism metric at this time, due to its small workforce and limited urban office-space footprint. 6 People Diversity and Inclusion Radiopharm recognises the benefits arising from employee, senior management and Board diversity, including a broader pool of high-quality employees, improving employee retention, accessing different perspectives and ideas and benefiting from all available talent. Diversity includes, but is not limited to, an individual's race, ethnicity, gender, sexual orientation, age, physical abilities, educational background, socioeconomic status, and religious, political, or other benefits. RAD's Corporate Governance Framework, outlining their Diversity Policy can be found on the Radiopharm Theranostics website: • www.radiopharmtheranostics.com/investors Pay Equality Radiopharm pays men and women equally in like-for-like roles. Despite only having a small number of employees we use external benchmarking to ensure proper and fair compensation. We work with experienced HR professionals to ensure fair and comparable remuneration packages in line with market benchmarking in the USA Biotech Industry. Wage Level As a specialist biotechnology company with a small, highly educated and specialist team, we ensure compliance with all USA federal and state laws with regards to remuneration for all employees. Child, Forces or Compulsory Labour Radiopharm considers child, forced and compulsory labour to be abhorrent. As a specialist biotechnology company with a small, highly educated and specialist team, the Company has not identified any direct exposure to child, forced or compulsory labour. The Company is below the A$100 million revenue threshold to report under the Modern Slavery Act in Australia. Health and Safety As a specialist biotechnology company, Radiopharm has effective workplace health and safety practices. Radiopharm will report on health and safety statistics in a future ESG report. Radiopharm has never reported a work-related fatality. Training Provided As a specialist biotechnology company with a small, highly educated team, training is not a material stakeholder capitalism metric for the Company. Radiopharm supports individuals to maintain their continuing professional education and to remain up-to-date with development in their respective fields of endeavour. 7 Prosperity Rate Of Employment With 10 employees during the reporting period, Radiopharm does not consider it worthwhile to perform further employment analysis at this time. Economic Contribution As a specialist biotechnology company, economic contribution is not considered a material stakeholder capitalism metric. This will be reviewed as the Company grows. Financial Investment Contribution Radiopharm's Annual Report includes full disclosure of research, capital expenditure, depreciation and amortisation. Annual Report. Total R&D Expenses As a specialist biotechnology company, research and development is fundamental to the Company and is comprehensively disclosed in the Annual Report. Total Tax Paid The Company reports Income tax in its Annual Report. 8 RAD ESG Performance Data Financial Year Ended 30 June 2024 Metric Notes 1 Unit 2 FY22 FY23 FY24 Target Annual Report & CGS Annual Report & CGS Annual Report & CGS 100 100 # Nil Nil Nil Nil $ $0 $0 $0 $0 Governance Governance performance reported in Annual Report and Corporate Governance Statement (CGS). Governance compliance with ASX Corporate Governance Council Principles and recommendations Anti-corruption Bribery and corruption incidents reported or identified Monetary losses from unethical behaviour Political Donations 3 4 Whistle-blower complaints Greenhouse Gas (GHG) emissions TCFD implementation Land use and ecological sensitivity Water consumption and withdrawal in water-stressed areas People Diversity and inclusion Directors • Female • Male • Other / not identified $ # Planet Carbon offset purchased for flights % 5 % 6 100 $0 0 Not measured 100 $0 0 Not measured $0 0 n/a Not measured %100 Refer to note Refer to note 7 Refer to note 8 9 $0 Refer to note % 33 67 - 33 67 - 33 67 - 40/40/20 10 40/40/20 1 Selected relevant metrics from World Economic Forum Report Measuring Stakeholder Capitalism: Towards Common Metrics and Consistent Reporting of Sustainable Value Creation, https://www.weforum.org/stakeholdercapitalism/our-metrics, 8.11.2022 3 Compliance assessed on ‘if not why not’ basis per ASX Corporate Governance Council Principles and Recommendations 2 4 5 6 All currency in Australian dollars (AUD). “#” = number. Total amount of monetary losses as a result of legal proceedings associated with fraud, insider trading, anti-trust, anti-competitive behaviour, market manipulation, malpractice, or violations of other related industry laws or regulations The Company does not consider GHG emissions to be a material stakeholder capitalism metric at this time, due to its small workforce and limited office-space footprint The Company does not consider TCFD implementation to be a material stake holder capitalism metric at this time, due to its small workforce and limited office-space footprint. 7 The Company does not consider land use and ecological sensitivity to be a material stakeholder capitalism metric at this time, as it operates from small offices in urban areas. 9 Ratios calculated as at 30 Jun. Senior Management includes Executive Chair, CEO, COO, CFO, CMO, CBO and Director level roles. 8 The Company does not consider water consumption to be a material stakeholder capitalism metric at this time, due to its small workforce and limited urban office-space footprint . 10 40/40/20 male/female/flexible ( www.wgea.gov.au/newsroom/4040-vision-a-new-initiative-to-bolster-gender-equality-in-the-asx200) 9 Metric Notes 1 Unit 2 FY22 FY23 FY24 Target 27 73 - 47 53 - 30 70 - 40/40/20 40/40/20 # Nil Nil Nil Nil # Nil Nil Nil $0 Nil $0 # % 5 Nil 4 7% 2 9% n/a Employees • Female • Male • Other / not identified Risk for incidents of child, forced or compulsory labour Identified cases of child, forced or compulsory labour in company or direct suppliers. Health and Safety • Recordable work-related injuries Discrimination and Harassment • Number of incidents • Total amount of monetary losses as a result of legal proceedings associated with law violations and employment discrimination. # % Nil $0 Nil Nil Nil $0 Prosperity Employment • New employee hires • Employee turnover Economic Contribution a. Revenue b. Operating costs c. Employee wages and benefits d. Payments to providers of capital Total R&D expenses Total costs related to research and development (excl. associated employment costs) Total R&D tax incentive Total tax offset received under R&D tax incentive (incl. associated employment costs) 11 $ Refer Annual Report Refer Annual Report Refer Annual Report $M 7.5 22.6 23.1 n/a $M 0 5.9 1.3 n/a T +61 3 9824 5254 E info@radiopharmtheranostics.com W radiopharmtheranostics.com A S X:RAD